We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

126 hedge funds and large institutions have $311M invested in ImmunityBio in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 26

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

0.93% more ownership

Funds ownership: 7.23% → 8.16% (+0.93%)

1% more funds holding

Funds holding: 125 → 126 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

20% less capital invested

Capital invested by funds: $390M → $311M (-$78.7M)

61% less call options, than puts

Call options by funds: $5.03M | Put options by funds: $13M

Holders
126
Holders Change
+1
Holders Change %
+0.8%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
51
Reduced
26
Closed
16
Calls
$5.03M
Puts
$13M
Net Calls
-$7.96M
Net Calls Change
+$3.73M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$16.2M
2
State Street
State Street
Massachusetts
+$12.4M
3
JP Morgan Chase
JP Morgan Chase
New York
+$6.3M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.23M
5
BlackRock
BlackRock
New York
+$3.06M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$3.57M
2
N
Nuveen
North Carolina
-$3.43M
3
CSS
Cubist Systematic Strategies
Connecticut
-$1.43M
4
Citigroup
Citigroup
New York
-$1.27M
5
EGM
Engineers Gate Manager
New York
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$68.5M +$16.2M +1,471,235 +26%
BlackRock
2
BlackRock
New York
$54.1M +$3.06M +278,411 +5%
State Street
3
State Street
Massachusetts
$51.8M +$12.4M +1,124,160 +27%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$14.8M +$512K +46,560 +3%
Northern Trust
5
Northern Trust
Illinois
$12.3M -$994K -90,296 -7%
JP Morgan Chase
6
JP Morgan Chase
New York
$11.6M +$6.3M +572,285 +92%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$8.62M +$1.32M +120,263 +16%
AH
8
Allen Holding
New York
$6.7M – – –
Morgan Stanley
9
Morgan Stanley
New York
$4.85M +$104K +9,434 +2%
Charles Schwab
10
Charles Schwab
California
$4.46M -$370K -33,654 -7%
Rafferty Asset Management
11
Rafferty Asset Management
New York
$4.39M +$366K +33,261 +8%
CS
12
Credit Suisse
Switzerland
$3.81M +$2.35M +213,636 +120%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$3.68M +$3.23M +293,098 +347%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$3.42M +$457K +41,531 +13%
HP
15
Harbourvest Partners
Massachusetts
$3.27M – – –
PAMS
16
Pictet Asset Management (Switzerland)
Switzerland
$3.03M +$3.42M +311,234 New
UBS Group
17
UBS Group
Switzerland
$2.71M +$2.77M +251,520 +925%
N
18
Nuveen
North Carolina
$2.6M -$3.43M -311,464 -54%
Goldman Sachs
19
Goldman Sachs
New York
$2.2M +$323K +29,340 +15%
Renaissance Technologies
20
Renaissance Technologies
New York
$2.02M +$2.29M +207,917 New
CAM
21
ClariVest Asset Management
California
$2.01M -$111K -10,093 -5%
Citigroup
22
Citigroup
New York
$1.8M -$1.27M -115,637 -39%
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
$1.77M -$362K -32,906 -15%
Swiss National Bank
24
Swiss National Bank
Switzerland
$1.65M +$941K +85,500 +102%
Citadel Advisors
25
Citadel Advisors
Florida
$1.61M +$1.41M +128,380 +352%
1
2 3 4 5

IBRX Hedge Fund Activity: Q3 2021 in Review

126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2021, worth a combined $311M — down 20% from $390M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new IBRX positions and 16 closed out — a net gain of 4 holders — while 51 added to existing stakes and 26 trimmed.

The largest buyer was Vanguard Group, adding an estimated $16.2M. The largest seller was First Trust Advisors, exiting entirely with an estimated $3.57M sold.

  • 126 institutional investors held ImmunityBio (IBRX) as of Q3 2021, up from 125 in Q2 2021.
  • Funds reported $311M of ImmunityBio stock for Q3 2021, down 20% quarter-over-quarter.
  • 20 funds opened new ImmunityBio positions in Q3 2021 and 16 closed out, a net change of +4 holders.
  • The largest ImmunityBio buyer in Q3 2021 was Vanguard Group, an estimated $16.2M added.
  • The largest ImmunityBio seller in Q3 2021 was First Trust Advisors, an estimated $3.57M sold.

Based on aggregated 13F filings for Q3 2021.